COVID-19 Vaccination Cuts Risk of Major Heart Attacks and Strokes, Landmark Study Finds

A landmark study has revealed that the updated COVID-19 vaccine offers profound protection far beyond the respiratory system, significantly reducing the risk of major heart attacks and strokes. Published in JAMA Internal Medicine, the research tracked over one million U.S. veterans, uncovering a cardioprotective effect that surprised even the investigators. The findings suggest that the cardiovascular burden of the pandemic may be substantially larger than official statistics reflect, driven by a hidden wave of undetected infections.[1][2][4]

The research, led by Dr. Ziyad Al-Aly at the VA St. Louis Health Care System, analyzed the health records of 1,039,659 patients during the 2024-2025 vaccination period. Researchers compared outcomes between roughly 349,000 veterans who received both a seasonal flu shot and an updated COVID-19 vaccine, and a control group of 690,000 who received only the flu shot. Over an eight-month follow-up, the vaccinated group demonstrated a 37.7% lower risk of experiencing a COVID-associated major adverse cardiovascular event, commonly referred to as MACE.[1][3][5][8]

MACE is a composite clinical endpoint that includes some of the most severe cardiac outcomes: cardiovascular death, myocardial infarction, stroke, and hospitalization for heart failure. When investigators broke down the data by specific events, the protective effect was striking. Vaccination was 57.9% effective at preventing COVID-associated cardiovascular death and 38.5% effective against COVID-associated heart attacks. Furthermore, the shots reduced the risk of hospitalization for heart failure by nearly 42%.[1][3]

While the reduction in documented COVID-linked events was significant, the finding that most captivated the medical community was the vaccine's impact on all-cause cardiac events. Even when researchers examined all heart attacks and strokes—regardless of whether a COVID-19 diagnosis appeared anywhere in the patient's medical record—vaccinated veterans still showed a nearly 24% lower risk.[4][6]

This broad reduction points to what epidemiologists are calling the "hidden burden" of the virus. Millions of cardiac events currently tallied by hospitals as idiopathic, or of unknown origin, likely have an invisible driver: unrecognized SARS-CoV-2 infection. Many individuals who feel briefly unwell never test for the virus, yet end up in an emergency room weeks later with a severe cardiovascular complication.[1][4][8]

The mechanism behind this phenomenon lies in how the virus interacts with the human vascular system. SARS-CoV-2 is not merely a respiratory pathogen; it actively infects the endothelial cells that line blood vessels, triggering systemic inflammation and blood-clotting disruption. This endothelial dysfunction can precipitate a cascade of deleterious cardiovascular events, destabilizing existing plaques or triggering micro-clots long after the acute respiratory symptoms have faded.[4][5][6]

By priming the immune system, the vaccine blunts viral replication and dampens this hyperimmune response, thereby lowering the risk of thrombotic complications and myocardial injury. The vaccine effectively prevents silent or mild infections from triggering the inflammatory cascade that precedes heart attacks and strokes, providing a systemic shield for the vascular network.[4][5][6]

The protective benefits were not distributed equally across all demographics. The study found that the cardiovascular shield was most pronounced among the most vulnerable populations, specifically those aged 75 and older. In this older cohort, the vaccine effectiveness against COVID-associated MACE jumped to 50.7%, translating to the largest absolute risk reduction observed in the study.[1][3]

Patients harboring pre-existing comorbidities such as hypertension, diabetes, or chronic kidney disease also saw outsized benefits from the updated formulation. For these individuals, whose cardiovascular systems are already under chronic stress, the prevention of a virus-induced inflammatory spike can mean the difference between stability and a catastrophic cardiac event.[5][6]

In terms of absolute numbers, the researchers estimated that the vaccine dropped the rate of COVID-associated MACE from about 5 in 10,000 to 3 in 10,000. While this absolute risk reduction might appear modest on an individual level, when extrapolated across the entire population of older adults in the United States, it translates to the prevention of thousands of major cardiac events and deaths annually.[3][4][6]

These findings also help contextualize early pandemic concerns regarding vaccine safety, specifically the risk of myocarditis, or inflammation of the heart muscle. During the initial rollout of the original mRNA formulations in 2021, a safety signal emerged, primarily affecting young males after their second dose. However, extensive monitoring has shown that this signal has largely resolved with the updated formulations.[4][7]

Current data indicates that the myocarditis risk from the 2024-2025 and 2025-2026 vaccine formulations is now at the background rate—indistinguishable from the general population. More importantly, multiple large-scale studies have consistently demonstrated that the risk of developing myocarditis or other severe cardiac complications from an actual COVID-19 infection is exponentially higher than any risk posed by the vaccine.[4][7]

For clinical practitioners, this data represents a paradigm shift in how vaccines are positioned within preventative medicine. Historically viewed strictly through the lens of infectious disease control, COVID-19 vaccination is increasingly being recognized as a vital component of chronic disease management and preventative cardiology.[5][6]

Dr. Al-Aly and his colleagues emphasize that these findings should prompt physicians to consider cardiovascular risk modulation when discussing vaccination with their patients. Recommending the shot is no longer just about preventing a severe cough or fever; it is a direct intervention to protect the structural integrity of the heart and brain.[5][6]

While the study's observational design precludes definitive causal claims, the massive sample size, robust statistical controls, and clear biologic plausibility lend immense credibility to the findings. The researchers acknowledge that the veteran demographic skews older and male, but the underlying biological mechanisms of endothelial protection are universally applicable.[5][6]

As the world continues to navigate the long-term aftermath of the pandemic, public health messaging must evolve to reflect this multifaceted appreciation of vaccine benefits. With uptake of the updated shots remaining stubbornly low among many demographics, communicating this profound cardioprotective effect may be the key to safeguarding population health in the years to come.[4][5][6]